|
|
Article: MASPIN PATENT ISSUES IN U.S.; LXR BIOTECHNOLOGY EXCLUSIVE LICENSEE
- Article from:
- PR Newswire
- Article date:
- February 7, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RICHMOND, Calif., Feb. 7 /PRNewswire/ -- LXR Biotechnology Inc. (AMEX: LXR) of Richmond, California, announced today that the U.S. Patent and Trademark Office issued a patent covering Maspin, a tumor suppressor protein in breast tissue. The protein was discovered by a group of scientists headed by Dr. Ruth Sager of The Dana-Farber Cancer Institute in Boston. The team of researchers at Dana-Farber, in collaboration with scientists from LXR Biotechnology, reported that Maspin levels in highly metastatic breast tumors are greatly reduced. As acknowledged by the National Cancer Institute in its 1996 Bypass Budget, Maspin gene activity may serve as a prognostic marker for the ...
Related newspaper, magazine, and journal articles:
|
|
Article: LXR Biotechnology Inc. Announces FDA Approval of ...
PR Newswire;
December 19, 1997 ;
700+ words
... ... data set," said L. David Tomei, chairman and chief ... date hereof. SOURCE LXR Biotechnology -0- 12/19/97 /CONTACT: L. David Tomei, Chairman & CEO ... Corporate Communications, of LXR Biotechnology Inc., 510-412-9100 ...
|
|